Drugs / 5-Fluorouracil (5-FU)
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06780111 | Jul 2025 → Jan 2032 expected | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03169777 | Aug 2018 → Jan 2019 | colorectal cancer | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03169764 | Dec 2017 → Jan 2019 | head and neck squamous cell carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03281369 | Oct 2017 → Oct 2025 | digestive system carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07554521 | Apr 2026 → Dec 2031 expected | esophageal squamous cell carcinoma, gastric adenocarcinoma, gastroesophageal adenocarcinoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00401323 | Jan 1998 → Jun 2003 | head and neck squamous cell carcinoma, metastatic neoplasm | Sanofi | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT06856447 Background | Jun 2024 → May 2025 overdue | colorectal cancer | toqa saad mohammed mohammed | Recruiting | No outcome recorded |
| Phase 1 | NCT01653470 Background | Oct 2012 → May 2017 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT06684158 Background | Nov 2024 → Mar 2027 expected | gastroesophageal junction adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05546411 Background | Jan → Aug 2023 | pancreatic adenocarcinoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT04062656 Background | Sep 2019 → Mar 2024 | gastric cancer, gastroesophageal junction adenocarcinoma | University Hospital, Essen | Unknown | No outcome recorded |
| Phase 3 | NCT00069121 Comparator | Apr 2003 → Apr 2011 | colorectal cancer | Hoffmann-La Roche | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-Fluorouracil (5-FU) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06780111 ↗ |
| Known as | 5-FU | “Drug: 5-fluorouracil (5-FU)” NCT07554521 ↗1“5-fluorouracil (5-FU)” NCT00401323 ↗ |
| Modality | Small molecule | “5-fluoro-2,4 (1H,3H)-pyrimidinedione” NCT03169764 ↗ |
| Route | Intravenous | “5-FU 425 mg/m\^2 IV bolus injection” NCT00069121 ↗ |